Amol Akhade, MD, discusses how cost shapes immunotherapy decisions and what standard cost-effectiveness measures miss for individual patients.
Amol Akhade, MD, MBBS
Advertisement
Articles by Amol Akhade, MD, MBBS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Dr Lee on the Optimal Duration of Adjuvant Osimertinib in EGFR+ NSCLC
5